David Oancea

Background: Cervical cancer remains a major global health burden with over 600,000 new cases and 340,000 deaths reported worldwide in 2020¹. The overwhelming majority of cases (>99%) are linked to persistent infection with high-risk human papillomavirus (HPV) strains, particularly HPV types 16 and 18^1,2. HPV is a non-enveloped DNA virus transmitted primarily through sexual contact³. Its genome encodes oncogenic proteins E6 and E7, which disrupt tumor suppressor pathways, especially p53 and Rb, to promote uncontrolled cell proliferation and genomic instability^2,4.Vaccines such as Gardasil-9 have significantly reduced the incidence of HPV infections and cervical precancerous lesions, particularly in populations with high vaccine coverage.³ However, gaps in vaccination, screening, and treatment accessibility—especially in low- and middle-income countries—continue to drive the global disease burden¹. Furthermore, current treatments for advanced or recurrent cervical cancer, such as chemotherapy and radiotherapy, offer limited long-term survival benefits, highlighting the need for targeted therapies that address the viral etiology and immune evasion mechanisms^2,5. Recent research has illuminated key pathways by which HPV drives tumor progression and resists immune surveillance. Notably, the viral oncoproteins E6 and E7 not only inactivate host tumor suppressors but also suppress immune recognition by downregulating MHC class I and interfering with interferon responses^4,6. These insights provide the basis for emerging molecular and immunologic therapies that target HPV-induced oncogenesis.

Objective: To evaluate and interpret recent advances in molecular and immunologic research targeting HPV-associated cervical cancer, with a focus on translational strategies that may enhance therapeutic efficacy and overcome immune resistance.

Methods: An online search was conducted using PubMed to identify relevant primary research studies published from 2017 through 2025. The search utilized keywords including “HPV E6,” “CRISPR HPV,” “therapeutic HPV vaccine,” “HPV immune evasion,” and “Hsp90 cervical cancer.”

Results: Building on the need to reverse tumor-induced immune suppression, Zeng et al.¹ demonstrated that Hsp90 regulates PD-L1 expression in HPV-positive cervical cancer cells. Inhibiting Hsp90 reduced PD-L1 levels and impaired immune evasion, while reintroducing PD-L1 restored tumor growth in vivo. To directly disable the viral oncogenes, Jubair et al.⁷ employed CRISPR/Cas9 to knock out HPV16 E6 and E7, resulting in p53 reactivation, complete tumor regression, and prolonged survival in murine models. Complementing this gene-editing approach, Celegato et al.² identified a small-molecule compound that disrupted E6-p53 interaction, restoring p53 activity and inducing apoptosis in HPV+ cancer cells. At the clinical interface, Stevanović et al.⁵ tested tumor-infiltrating lymphocyte (TIL) therapy targeting HPV antigens in metastatic cervical cancer patients. Two achieved complete responses, with others showing partial or stable disease, indicating feasibility of antigen-directed immunotherapy. Finally, Galliverti et al.⁶ developed a nanoparticle-based therapeutic vaccine targeting HPV16 E7 that elicited strong CD8⁺ T-cell responses, induced tumor regression, and promoted immunologic memory in animal models.

Conclusion: These five studies highlight a promising convergence of molecular and immunologic strategies for HPV-associated cervical cancer. From gene-editing platforms and checkpoint modulation to adoptive cell transfer and nanoparticle vaccines, each approach addresses a distinct aspect of the disease’s pathophysiology. Together, these strategies chart a path toward precision immunotherapy and gene-directed treatment paradigms. Further preclinical development and clinical validation are essential to translate these findings into viable, personalized therapies that can overcome current treatment limitations and improve patient outcomes.

Works Cited:

1. Zeng Z, et al. HPV E6/E7-mediated TGF-β1 downregulation promotes EMT in cervical cancer. J Cell Biochem. 2018;119(5):3896–3906.
2. Celegato M, et al. E6/E7 inhibition restores p53 function and suppresses cervical cancer growth. Oncogene. 2020;39(6):1212–1223.
3. Trimble CL, et al. Therapeutic HPV vaccines in clinical trials. J Clin Invest. 2021;131(14):e152725.
4. Olmedo-Nieva L, et al. Role of HPV E6 and E7 oncoproteins in immune evasion. J Virol. 2020;94(5):e01539-19.
5. Stevanović S, et al. TIL therapy for HPV-associated cervical cancer. J Clin Oncol. 2015;33(15_suppl):3009.
6. Galliverti G, et al. Nanoparticle therapeutic vaccine for HPV16+ tumors. Nat Commun. 2023;14(1):350.
7. Jubair L, et al. CRISPR/Cas9 targeting of HPV16 E6 and E7 induces apoptosis and tumor regression. Mol Ther Oncolytics. 2021;20:305–316.